Ny strategi syns, men olivoljeindustrin är pressad OptiCepts omsättning för Q2 uppgick till 2,2 mkr ...
Access pipeline fortsätter accelerera… Zwipe har 10 pågående så kallade Proof of Concept (PoC), elle...
För tredje kvartalet i rad redovisade Ferroamp nytt försäljningsrekord.
Redeye states that Harm Reduction Group’s Q2 2023 report was weaker on top-line than expected.
No material news in the report Next milestone, pirepemat study full recruitment (YE'23e) Webcast tod...
Redeye saw sales and results that were below our expectations.
Mangold uppdaterar investmentbolaget Capsek vars onoterade innehav i en tidig fas (scale-up) har vux...
Redeye considers Xbrane’s Q2 weak due to slower sales ramp-up than anticipated and postponed profita...
Redeye updates our outlook ahead of the European and the US launch of XVIVO’s Heart cold continuous ...
Redeye updates its view on CI Games. While FY 2022 was a year of consolidation, 2023e will be the st...
Since our Q1 update, Lipigon signed a deal with Leaderna for Greater China and reported a favourable...
Redeye updates its view on M.O.B.A. Network following its Q2 2023 report.
Yesterday, Evaxion announced that Christian Kanstrup has been appointed the CEO of Evaxion, taking o...
Redeye’s short comment on the new CEO appointment.
This afternoon, Vow announced that it has been awarded a retrofit contract with a major (undisclosed...
Redeye provides a research update on Faron Pharmaceuticals following the company’s recent half-year ...
Flowscape rapporterade ett starkt kvartal med ökad omsättning och förbättrat resultat.
Umida levererade ett resultat i linje med förväntningarna i Q2.
Loihde reports its Q2 result on Thursday. While SeSo is expected to drive strong Q2 growth, the curr...
Redeye comments on Klaria Pharma’s Q2 2023 report. Despite the recent rights issue at the end of 202...
